The development of monoclonal antibody PCSK9 inhibitors has allowed for dramatic lowering of LDL and CV events, but what new analysis adds knowledge to the benefits of PCSK9?  Dr. Bernie reviews the practice impacting results of a prespecified analysis of FOURIER trial published in JAMA-Cardiology April 2020, to evaluate the LDL cholesterol-lowering effect of Evolocumab on different types and sizes of myocardial infarction.

The development of monoclonal antibody PCSK9 inhibitors has allowed for dramatic lowering of LDL and CV events, but what new analysis adds knowledge to the benefits of PCSK9? Dr. Bernie reviews the practice impacting results of a prespecified analysis of FOURIER trial published in JAMA-Cardiology April 2020, to evaluate the LDL cholesterol-lowering effect of Evolocumab on different types and sizes of myocardial infarction.

25 FOURIER and Evolocumab

Dr. Bernard Monteleone, former Head of Cardiology at St. Francis Hospital in New York, gives an informed analysis of highly-anticipated trials and whether or not their findings could impact clinical practice guidelines and reduce the risk of cardiovascular disease.

Share 25 FOURIER and Evolocumab

Sign up to save your podcasts

25 FOURIER and Evolocumab

25 FOURIER and Evolocumab